Abstract: The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases.

Abstract: The present invention provides a self-assembled nanocluster containing a carbon nanomaterial modified with a functional group represented by the following formula (I): —Y1—R (I) wherein Y1 represents a divalent linking group, and R represents an organic group.

Abstract: Disclosed are pharmaceutical compositions containing saposin C and phosphatidylserine that are useful for treating various cancers.

Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients).

Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.

Abstract: The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to ?-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to ?-cells that stabilize and activate CRISPR effector proteins comprising at least one destabilization domain, to enable CRISPR-based genome editing and transcriptional activation or repression in ?-cells.

Abstract: The present invention provides compositions comprising Verteporfin and other anticancer compounds linked to a hydrophilic peptide through a degradable linker molecule to allow the anticancer compounds to penetrate tissues via in situ administration. The compounds of the present invention are useful for sensitizing tumor cells to radiotherapy, preventing recurrence of tumors after surgical resection and for treating remaining unremoved cancer cells at the site of the tumor.

Abstract: The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

Abstract: The present invention relates to conjugates comprising an immunotoxin linked to a therapeutic agent, wherein said immunotoxin comprises a binding domain fused to an adenosine diphosphate (ADP) ribosylating toxin, pharmaceutical compositions comprising said conjugates, and methods for the preparation of said immunotoxins.

Abstract: Method of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

Abstract: Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).

Abstract: Extracellular drug conjugates (EDCs) targeting CD38 are useful in the treatment of diseases such as cancer and immune disorders, including asthma.

Abstract: Disclosed herein is a method for treating a cancer, the method includes following operations. A pharmaceutical composition is administered to a subject in need. The pharmaceutical composition includes a medium and a plurality of cisplatin-loaded microbubbles dispersed in the medium. Each cisplatin-loaded microbubble includes a shell portion and a core portion. The shell portion includes a plurality of albumin molecules and a plurality of first cisplatin molecules covalently bonding to the albumin molecules. The core portion is surrounded by the shell portion, wherein the core portion includes a mixture of inert gas and a plurality of second cisplatin molecules. Ultrasound energy is then applied to a tumor of the subject to break the cisplatin-loaded microbubbles.

Abstract: Disclosed is a new vector for pharmacologically active water-insoluble molecules. These nanovectors, which are in the form of carbon nanoplatforms, are capable of solubilising the active molecules while reducing the side effects of the treatments. Also disclosed are the processes for synthesizing these nanoplatforms, as well as to the use thereof as a drug, particularly in the treatment of brain tumors.

Abstract: Provided herein, in some embodiments, are materials and methods for treating hemophilia A in a subject ex vivo or in vivo. Also provided herein, in some embodiments, are materials and methods for knocking in a coding sequence encoding a synthetic FVIII having a B domain substitute into a genome.

Abstract: In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some aspects, methods of detecting high risk drusen are provided. In some aspects, presence of one or more high risk drusen in an eye indicates increased likelihood of developing AMD, GA, or advanced AMD or increased likelihood of rapid progression of AMD. In some embodiments, methods comprise detecting drusen containing or in close proximity to complement activation. In some embodiments methods comprise detecting one or more drusen having inflamed endothelium underlying or in close proximity thereto. In some embodiments methods comprise detecting eye-derived extracellular microvesicles, e.g., exosomes, in a body fluid. In some embodiments methods comprise detecting Th17 cells or a Th17 biomarker in a body fluid. In some embodiments the Th17 biomarker is a cytokine. Methods may be applied individually or in any combination.

Abstract: An object is to provide a method of inspection enabling a slurry of a batch resulting in abnormal accumulation to be identified in advance, and to provide an SWCNT slurry for bioimaging that has undergone the inspection. In order to solve the above problems, the present invention provides a method for inspecting a semiconductor single-walled carbon nanotube (SWCNT) slurry for bioimaging, the slurry comprising: semiconductor SWCNTs oxidized by being directly irradiated with ultraviolet rays in atmosphere and a dispersant composed of an amphiphilic substance that coats surfaces of the SWCNTs, the method comprising: using at least two types of methods selected from the group consisting of absorption spectroscopy, a photoluminescence method, and particle size measurement, confirming that an average particle size of the semiconductor SWCNTs is smaller than 10 nm, isolated dispersibility of the semiconductor SWCNTs is high, and/or the semiconductor SWCNTs are oxidized.

Abstract: One embodiment of the present invention relates to a nanoemulsion and a preparation method therefor, the nanoemulsion comprising an oil component, a surfactant, and an aqueous component, wherein the aqueous component comprises a water-soluble active ingredient, a polysaccharide, and hyaluronic acid.

Abstract: The present invention relates to a compressed solid composition for MRI comprising a physiologically acceptable manganese (II) compound, its preparation and use for preparing an oral solution.

Abstract: The present invention relates to compositions comprising B-cell maturation antigen-directed nanoparticles and methods for using the same.

Abstract: An imaging nanoparticle comprising a plant virus particle having an interior surface and an exterior surface, an imaging agent that is linked to the interior and/or exterior surface, and a layer of biocompatible mineral such as silica coated over the exterior surface, is described. The imaging nanoparticle can be used in method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed.

Abstract: The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.

Abstract: Proposed is to provide a size-varying bubble complex and a method of preparing the same. More specifically, the size-varying bubble complex and the method of preparing the same are proposed, wherein the bubble complex is capable of being repeatedly varied in size by changing phases of perfluorocarbon by external stimuli, by including a shell that encapsulates a core made of the perfluorocarbon and protects the core by expanding and contracting together when the core expands and contracts.

Abstract: This imaging method of AMPA receptors in the brain of primate organisms involves a step in which a substance which is administered to the primate organism and which selectively bonds to AMPA receptors in the brain of the primate organism and has a radiolabel is transported into the brain and made to bond with AMPA receptors in the brain, and, by detecting radiation emitted from the substance bonded to the AMPA receptors in the brain, data is obtained relating to the distribution and/or expression level of the AMPA receptors in the brain.

Abstract: Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter and astrocyte elevated gene 1 (AEG-1) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols, e.g. for imaging and/or treating spontaneous metastasis. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.

Abstract: A composition comprising catalase, a preparation method and a use thereof, and a method for killing tumor cells are provided. The composition comprises a radionuclide labeled to a biomacromolecule, a soluble alginate and catalase. The composition can be injected into the tumor through an interventional treatment. A gel is formed when an alginate ion in the composition enters the tumor and encounters a calcium ion, such that the radionuclide and the catalase are uniformly confined in the tumor. The composition comprising catalase utilizes catalase to decompose dissolved oxygen generated from hydrogen peroxide in the tumor to advance the hypoxic state of the tumor cells, and the tumor cells are killed with radiation after the hypoxic state thereof has been advanced, and thus the invention has good prospects for applications in cancer therapy.

Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.

Abstract: Systems and methods of disinfection a facility are described herein. In at least one embodiment, the systems include a thermal-based imaging sensor configured to detect thermal infrared radiation in the facility, the facility having a plurality of regions; an ultraviolet light source to provide ultraviolet radiation to disinfect the facility; and a controller configured to: receive an input signal from the thermal-based sensor, the input signal comprising temperature data based on the detected thermal infrared radiation in the facility; determine a presence or an absence of a person in one of the plurality of regions of the facility based on the temperature data; and upon determining the absence of a person in the one of the plurality of regions of the facility, activate the ultraviolet light source to disinfect the one of the plurality of regions.

Abstract: Provided is a UV sterilizer including an illumination unit, a cover that has an open hole in an upper surface thereof and supports the illumination unit, and a body that is provided underneath the cover and secures an illumination distance between the illumination unit and an illumination target object. The body is composed of a first body and a second body into which the first body is inserted. The first body and the second body are separably combined with each other.

Abstract: A UV disinfection apparatus (1, 1?), with a housing (10) and a UV light source (11) therein. An electrical energy store (15) is provided in the housing (10). The housing (10) is sealed off, and a sensor is provided therein, which activates the UV light source (11) only when the laundry treatment device (2) is in operation. Also, a method for disinfecting laundry accommodated in a rotatable drum (21) by means of a UV disinfection apparatus (1, 1?) which is autonomous placed into or set in the drum (21) together with the laundry. The UV light source (11) is only activated when the laundry treatment device is in operation.

Abstract: An embodiment discloses a light source module including: a fixing plate configured to extend in a first direction; a circuit board disposed on the fixing plate; a plurality of ultraviolet light emitting elements disposed on the circuit board in the first direction; a first reflection plate coupled to one side of the fixing plate; and a second reflection plate coupled to the other side of the fixing plate, wherein the first reflection plate and the second reflection plate include inclined surfaces which become closer to each other as the distance from the circuit board increases and the inclined surface of the first reflection plate and the inclined surface of the second reflection plate are disposed to be spaced apart in the first direction and disposed on a side surface of a target structure, and an ultraviolet ray irradiating apparatus including the same.

Abstract: A sterilization system may include an ozone generator, a buffer chamber, an ozone concentration monitor or cuvette, a treatment chamber, one or more valves, and a controller. The ozone generator generates a flow of ozone. The buffer chamber stores the flow of ozone. The ozone cuvette monitors a concentration of ozone from the buffer chamber. The treatment chamber receives a material for sterilization, and receives a flow of air/ozone. The controller selectively and independently controls each of the valves. The sterilization system including first and second operating modes. In the first operating mode, the treatment chamber is isolated from the ozone generator and the buffer chamber such that ozone is not being supplied to the treatment chamber. In the second operating mode, the treatment chamber is in communication with the ozone generator and the buffer chamber such that ozone is being supplied to the treatment chamber.

Abstract: A divider for a sterilization filter basket for sterilizing medical instruments has two lateral wall sections and a central wall section therebetween. The divider is substantially flat in configuration, and the central wall section is perforated by a multiplicity of openings. One lateral wall section or both lateral wall sections has/have a slit-shaped notch, so that the lateral region of the lateral wall section, which is separated by the slit-shaped notch, is formed as a resilient section that has a number of lateral protrusions. If only one lateral wall section is formed in this way, then the other lateral wall section has a number of protrusions that extend at least partially in the lateral direction and at least partially in a direction perpendicular to the extension plane of the central wall section.

Abstract: A purifying method includes determining an intended position that ejected matter ejected from an ejecting apparatus is made to reach; judging whether an object touches the ejected matter within a period of time from ejection of the ejected matter from the ejecting apparatus to reaching of the ejected matter to the intended position based on positional information on the object, the positional information being obtained by a first sensor; and controlling, based on a result of the judging, how the ejecting apparatus ejects the ejected matter into an area including the intended position.

Abstract: Disclosed is a process for treating a stale gas, involving the following steps: circulation of the stale gas in a gas/liquid contactor, called a contactor, and then circulation of the stale gas in a filter unit, called a filter unit, the process involving, in the contactor, placing a circulating liquid in contact with the stale gas, the circulating liquid having a temperature of between 2 and 15° C., preferably between 5 and 10° C., and also to a treatment unit for performing the process including a gas/liquid contactor and a filter unit.

Abstract: A deodorization module including a housing having a suction port and a discharge port formed therein, a fan disposed between the suction port and the discharge port, a photocatalytic filter disposed between the suction port and the fan, a light source module including a substrate and an ultraviolet light source and configured to irradiate the photocatalytic filter with ultraviolet light, and an ion generator disposed between the fan and the discharge port.

Abstract: The present invention relates to a composition of a calcium phosphate such as tetracalcium phosphate or ?-TCP and an additive compound selected from nucleic acid or nucleotides, phospho(enol)pyruvic acid and phosphocreatine. The composition may be used as a tissue adhesive.

Abstract: In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.

Abstract: An absorbable iron-based instrument is provided having an iron-based substrate, a zinc-containing protector in contact with the iron-based substrate, and a degradable polyester in contact with the iron-based substrate and/or the zinc-containing protector. The range of the ratio of the mass of the zinc-containing protector to the mass of the iron-based substrate is 1:200 to 1:2. In the degradable polyester, the mass fraction of a low-molecular-weight part with a molecular weight of less than 10,000 is less than or equal to 5%; alternatively, in the degradable polyester, the mass fraction of a residual monomer is less than or equal to 2%.

Abstract: A metal surgical instrument having improved corrosion resistance, wherein the surgical instrument is treated with a biocompatible polyphenyl ether-based polymeric coating.

Abstract: Disclosed is a method of preparing PCL patch tissue regeneration scaffold comprising preparing solution by adding polycaprolactone (PCL) and an acid to an organic solvent; preparing an electrospinning solution by adding a growth factor to the solution and stirring; and collecting nanofibers arranged in a spindle shape on a collector by connecting the electrospinning solution prepared to a syringe pump and operating the electrospinning device.

Abstract: The particle (1) is suitable for the manufacture of an implantable soft tissue engineering material and comprises: a three-dimensionally warped and branched sheet (2) where (i) the three-dimensionally warped and branched sheet (2) is made from a biocompatible material having a Young's modulus of 1 kPa to 1 GPa; (ii) the three-dimensionally warped and branched sheet (2) has an irregular shape which is encompassed in a virtual three-dimensional envelope (3) having a volume VE; (iii) the three-dimensionally warped and branched sheet (2) has a mean sheet thickness T; iv) the three-dimensionally warped and branched sheet (2) has a volume VS; (v) the particle (1) has a Young's modulus of 100 Pa to 15 kPa; and (vi) the particle (1) further comprises a number of protrusions where the three-dimensionally warped and branched sheet (2) reaches the envelope (3); (vii) the particle (1) has a number of interconnected channel-type conduits (5) defined by the branching of the sheet (2) and/or by voids in the sheet (2); and (

Abstract: A haemostat agent in the form of a multi-layer patch comprising at least first and second layers, wherein said first layer comprises a composition comprising fibrous ?-chitin (which may be sourced from a marine source such as squid pens) and one or more biocompatible polymer (for example, a polyethylene glycol (PEG) polymer or sodium polyphosphate (PolyP)), and said second layer comprises a film layer comprising fibrous ?-chitin. In one particular application, the haemostat agent is used for treating carotid artery injury associated with endonasal surgery.

Abstract: Provided is a composition for a scaffold having a mineral coating similar to bone. Also provided is a method for mineral coating a scaffold so as to promote mineral coating of the scaffold with a plate-like nanostructure and a carbonate-substituted, calcium-deficient hydroxyapatite phase.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise an ECM-mimicking composition comprising poly(glycerol sebacate) (PGS) and a cytokine.

Abstract: The present application relates to injectable tissue products and their production and use thereof. The tissue products include a group of acellular tissue matrix particles, a bioadhesive, and a biocompatible polymer. The tissue products may be used to treat hernia defects.

Abstract: The present invention relates to a fibrous nerve conduit for promoting nerve regeneration, comprising a channel, the channel having diameter controllable ends, the channel is adjustable to suturing to a proximal and distal end of a severed nerve, the conduit further comprises a PCL (MW: 70 KDa) with concentration of 10-15% and PLGA (MW: 50 KDa, 50:50) with concentration of 10-18%.

Abstract: The present invention provides compositions and methods for the regeneration of tissue. In particular, the present invention provides mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) for bladder regeneration.

Abstract: Methods are disclosed which combine electrospinning and a sacrificial template, such as with additive manufacturing (AM), to produce fibrous microvascular scaffolds which are biodegradable, porous, and easily handled. In one example, a process for fabricating a fibrous network construct is disclosed. The method includes electrospinning a first layer of fibrous material; printing a micropatterned sacrificial template; transferring the micropatterned sacrificial template onto the electrospun fibers; electrospinning a second layer of fibrous biomaterial onto the micropatterned sacrificial template thereby encapsulating the template and generating a construct with two layers; and removing the sacrificial template, producing a fibrous construct with channels or microstructures formed therein. Also disclosed are fibrous constructs and scaffolds produced by the provided methods.